Cyclo Therapeutics Ownership 2024 | Who Owns Cyclo Therapeutics Now?

Overview RevenueFinancials Chart

Institutional Ownership

15.33%

Insider Ownership

39.91%

Retail Ownership

44.77%

Institutional Holders

16.00

Cyclo Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ARMISTICE CAPITAL, LLC	9.47%	0.01%	603,000	-327,000	-35.16%	506,580,000	Mar 31, 2023
VANGUARD GROUP INC	3.99%	-	253,882	-	-	213,286,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.82%	-	52,253	-	-	43,944,000	Mar 31, 2023
STATE STREET CORP	0.44%	-	28,300	-	-	23,800,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.29%	-	18,501	18,501	100.00%	15,559,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.19%	0.00%	11,953	7,168	149.80%	10,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.04%	-	2,311	10	0.43%	1,941,000	Mar 31, 2023
CLEAR STREET MARKETS LLC	0.03%	0.00%	1,725	1,725	100.00%	1,000	Mar 31, 2023
UBS GROUP AG	0.03%	-	1,640	-1,170	-41.64%	1,378,000	Mar 31, 2023
ROYAL BANK OF CANADA	0.01%	-	746	-	-	1,000,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.01%	-	600	-	-	504,000	Mar 31, 2023
MORGAN STANLEY	0.01%	-	443	-	-	372,000	Mar 31, 2023
BLACKROCK INC.	0.01%	-	362	-	-	304,000	Mar 31, 2023
PRINCETON GLOBAL ASSET MANAGEMENT LLC	0.00%	0.00%	300	300	100.00%	252,000	Mar 31, 2023
FMR LLC	0.00%	-	300	300	100.00%	252,000	Mar 31, 2023
IFP ADVISORS, INC	0.00%	-	13	-	-	55,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-18	-100.00%	-	Mar 31, 2023
LPL FINANCIAL LLC	-	-	-	-10,080	-100.00%	-	Mar 31, 2023

Cyclo Therapeutics's largest institutional shareholder is ARMISTICE CAPITAL, LLC, holding 9.47% of the company's total share outstanding, currently valued at $506.58M. The top 10 institutional shareholders own together 15.30% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ARMISTICE CAPITAL, LLC	9.47%	0.01%	603,000	-327,000	-35.16%	506,580,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.19%	0.00%	11,953	7,168	149.80%	10,000	Mar 31, 2023
CLEAR STREET MARKETS LLC	0.03%	0.00%	1,725	1,725	100.00%	1,000	Mar 31, 2023
PRINCETON GLOBAL ASSET MANAGEMENT LLC	0.00%	0.00%	300	300	100.00%	252,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.82%	-	52,253	-	-	43,944,000	Mar 31, 2023
VANGUARD GROUP INC	3.99%	-	253,882	-	-	213,286,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.29%	-	18,501	18,501	100.00%	15,559,000	Mar 31, 2023
IFP ADVISORS, INC	0.00%	-	13	-	-	55,000	Mar 31, 2023
STATE STREET CORP	0.44%	-	28,300	-	-	23,800,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.01%	-	600	-	-	504,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.04%	-	2,311	10	0.43%	1,941,000	Mar 31, 2023
UBS GROUP AG	0.03%	-	1,640	-1,170	-41.64%	1,378,000	Mar 31, 2023
ROYAL BANK OF CANADA	0.01%	-	746	-	-	1,000,000	Mar 31, 2023
MORGAN STANLEY	0.01%	-	443	-	-	372,000	Mar 31, 2023
FMR LLC	0.00%	-	300	300	100.00%	252,000	Mar 31, 2023
BLACKROCK INC.	0.01%	-	362	-	-	304,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-18	-100.00%	-	Mar 31, 2023
LPL FINANCIAL LLC	-	-	-	-10,080	-100.00%	-	Mar 31, 2023

The largest Cyclo Therapeutics shareholder by % of total assets is ARMISTICE CAPITAL, LLC. The company owns 603.00K shares of Cyclo Therapeutics (CYTH), representing 0.01% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
CITADEL ADVISORS LLC	0.29%	-	18,501	18,501	100.00%	15,559,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.19%	0.00%	11,953	7,168	149.80%	10,000	Mar 31, 2023
CLEAR STREET MARKETS LLC	0.03%	0.00%	1,725	1,725	100.00%	1,000	Mar 31, 2023
FMR LLC	0.00%	-	300	300	100.00%	252,000	Mar 31, 2023
PRINCETON GLOBAL ASSET MANAGEMENT LLC	0.00%	0.00%	300	300	100.00%	252,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.04%	-	2,311	10	0.43%	1,941,000	Mar 31, 2023
BLACKROCK INC.	0.01%	-	362	-	-	304,000	Mar 31, 2023
MORGAN STANLEY	0.01%	-	443	-	-	372,000	Mar 31, 2023
ROYAL BANK OF CANADA	0.01%	-	746	-	-	1,000,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.01%	-	600	-	-	504,000	Mar 31, 2023
STATE STREET CORP	0.44%	-	28,300	-	-	23,800,000	Mar 31, 2023
IFP ADVISORS, INC	0.00%	-	13	-	-	55,000	Mar 31, 2023
VANGUARD GROUP INC	3.99%	-	253,882	-	-	213,286,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.82%	-	52,253	-	-	43,944,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-18	-100.00%	-	Mar 31, 2023
UBS GROUP AG	0.03%	-	1,640	-1,170	-41.64%	1,378,000	Mar 31, 2023
LPL FINANCIAL LLC	-	-	-	-10,080	-100.00%	-	Mar 31, 2023
ARMISTICE CAPITAL, LLC	9.47%	0.01%	603,000	-327,000	-35.16%	506,580,000	Mar 31, 2023

As of Mar 31 2023, Cyclo Therapeutics's largest institutional buyer is CITADEL ADVISORS LLC. The company purchased 18.50K stocks of CYTH, valued at $15.56M.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ARMISTICE CAPITAL, LLC	9.47%	0.01%	603,000	-327,000	-35.16%	506,580,000	Mar 31, 2023
LPL FINANCIAL LLC	-	-	-	-10,080	-100.00%	-	Mar 31, 2023
UBS GROUP AG	0.03%	-	1,640	-1,170	-41.64%	1,378,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-18	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.82%	-	52,253	-	-	43,944,000	Mar 31, 2023
VANGUARD GROUP INC	3.99%	-	253,882	-	-	213,286,000	Mar 31, 2023
IFP ADVISORS, INC	0.00%	-	13	-	-	55,000	Mar 31, 2023
STATE STREET CORP	0.44%	-	28,300	-	-	23,800,000	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	0.01%	-	600	-	-	504,000	Mar 31, 2023
ROYAL BANK OF CANADA	0.01%	-	746	-	-	1,000,000	Mar 31, 2023
MORGAN STANLEY	0.01%	-	443	-	-	372,000	Mar 31, 2023
BLACKROCK INC.	0.01%	-	362	-	-	304,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.04%	-	2,311	10	0.43%	1,941,000	Mar 31, 2023
PRINCETON GLOBAL ASSET MANAGEMENT LLC	0.00%	0.00%	300	300	100.00%	252,000	Mar 31, 2023
FMR LLC	0.00%	-	300	300	100.00%	252,000	Mar 31, 2023
CLEAR STREET MARKETS LLC	0.03%	0.00%	1,725	1,725	100.00%	1,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.19%	0.00%	11,953	7,168	149.80%	10,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.29%	-	18,501	18,501	100.00%	15,559,000	Mar 31, 2023

As of Mar 31 2023, Cyclo Therapeutics's biggest institutional seller is ARMISTICE CAPITAL, LLC. The company sold -0.33M shares of CYTH, valued at $506.58M.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
CITADEL ADVISORS LLC	0.29%	-	18,501	18,501	100.00%	15,559,000	Mar 31, 2023
CLEAR STREET MARKETS LLC	0.03%	0.00%	1,725	1,725	100.00%	1,000	Mar 31, 2023
FMR LLC	0.00%	-	300	300	100.00%	252,000	Mar 31, 2023
PRINCETON GLOBAL ASSET MANAGEMENT LLC	0.00%	0.00%	300	300	100.00%	252,000	Mar 31, 2023

Cyclo Therapeutics's largest new institutional shareholder by number of shares is CITADEL ADVISORS LLC, purchased 18.50K shares, valued at $15.56M, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
LPL FINANCIAL LLC	-	-	-	-10,080	-100.00%	-	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-18	-100.00%	-	Mar 31, 2023

Cyclo Therapeutics's largest sold out institutional shareholder by shares sold is LPL FINANCIAL LLC, sold -10.08K shares, valued at -, as of undefined.

Cyclo Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
VANGUARD VALLEY FORGE FUNDS	0.01%	2,677	-	-	Dec 31, 2023
FIDELITY COMMONWEALTH TRUST	0.00%	7,085	-	-	Feb 29, 2024
NATIONWIDE MUTUAL FUNDS	0.00%	146,266	-4,730	-3.13%	Jan 31, 2024
VANGUARD INDEX FUNDS	0.00%	483,361	201,334	71.39%	Dec 31, 2023
MASTER INVESTMENT PORTFOLIO	0.00%	531	531	-	Dec 31, 2023
DFA INVESTMENT DIMENSIONS GROUP INC	0.00%	5,124	-	-	Jan 31, 2024
EQ ADVISORS TRUST	0.00%	1,853	-	-	Dec 31, 2023

Cyclo Therapeutics's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 2.68K shares, compromising 0.01% of its total assets.

Cyclo Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Mar, 23	16	14.29%
31 Dec, 22	14	16.67%
30 Sep, 22	12	-
30 Jun, 22	12	-
31 Mar, 22	12	-7.69%
31 Dec, 21	13	8.33%
30 Sep, 21	12	20.00%
30 Jun, 21	10	25.00%
31 Mar, 21	8	14.29%
31 Dec, 20	7	-

As of 31 Mar 23, 16 institutions are holding Cyclo Therapeutics's shares, representing an increase of 14.29% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Mar, 23	976,329	-24.12%
31 Dec, 22	1,286,593	223.51%
30 Sep, 22	397,699	-1.12%
30 Jun, 22	402,185	-7.32%
31 Mar, 22	433,964	-5.27%
31 Dec, 21	458,091	38.40%
30 Sep, 21	330,981	25.53%
30 Jun, 21	263,669	269.40%
31 Mar, 21	71,378	-87.97%
31 Dec, 20	593,267	-

Cyclo Therapeutics (CYTH) has 976.33K shares outstanding as of 31 Mar 23, down -24.12% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Mar, 23	15.33%	-24.12%
31 Dec, 22	20.20%	223.51%
30 Sep, 22	6.24%	-1.12%
30 Jun, 22	6.31%	-7.32%
31 Mar, 22	6.81%	-4.11%
31 Dec, 21	7.10%	36.69%
30 Sep, 21	5.20%	5.14%
30 Jun, 21	4.94%	10.76%
31 Mar, 21	4.46%	-95.54%
31 Dec, 20	100.00%	-

As of 31 Mar 23, Cyclo Therapeutics is held by 15.33% institutional shareholders, representing a -24.12% negative growth compared to 31 Dec 22.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Mar, 23	2	-50.00%
31 Dec, 22	4	300.00%
30 Sep, 22	1	-
30 Jun, 22	1	-80.00%
31 Mar, 22	5	25.00%
31 Dec, 21	4	-20.00%
30 Sep, 21	5	-
30 Jun, 21	5	-
31 Mar, 21	-	-
31 Dec, 20	-	-

2 institutional shareholders have increased their position in CYTH stock as of 31 Mar 23 compared to 4 in the previous quarter (a -50.00% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Mar, 23	2	-
31 Dec, 22	-	-100.00%
30 Sep, 22	1	-83.33%
30 Jun, 22	6	200.00%
31 Mar, 22	2	-60.00%
31 Dec, 21	5	150.00%
30 Sep, 21	2	-
30 Jun, 21	-	-100.00%
31 Mar, 21	1	-
31 Dec, 20	-	-

2 institutional shareholders have reduced their position in CYTH stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Mar, 23	16	14.29%	976,329	-24.12%	15.33%	-24.12%	2	-50.00%	2	-
31 Dec, 22	14	16.67%	1,286,593	223.51%	20.20%	223.51%	4	300.00%	-	-100.00%
30 Sep, 22	12	-	397,699	-1.12%	6.24%	-1.12%	1	-	1	-83.33%
30 Jun, 22	12	-	402,185	-7.32%	6.31%	-7.32%	1	-80.00%	6	200.00%
31 Mar, 22	12	-7.69%	433,964	-5.27%	6.81%	-4.11%	5	25.00%	2	-60.00%
31 Dec, 21	13	8.33%	458,091	38.40%	7.10%	36.69%	4	-20.00%	5	150.00%
30 Sep, 21	12	20.00%	330,981	25.53%	5.20%	5.14%	5	-	2	-
30 Jun, 21	10	25.00%	263,669	269.40%	4.94%	10.76%	5	-	-	-100.00%
31 Mar, 21	8	14.29%	71,378	-87.97%	4.46%	-95.54%	-	-	1	-
31 Dec, 20	7	-	593,267	-	100.00%	-	-	-	-	-

Cyclo Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Oct 23, 2023	Rafael Holdings, Inc.	10 percent owner	-	P-Purchase	Buy	2,766,467	$0.95	$2.63M	2,766,467

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Oct 23, 2023	Rafael Holdings, Inc.	10 percent owner	-	P-Purchase	Buy	2,766,467	$0.95	$2.63M	2,766,467

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Dec 28, 2023	Cross Shawn	director	-		Sell	-	-	-	-

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Feb 15, 2024	Sieger Markus	director	-	A-Award	Buy	14,004	-	-	310,679
Feb 15, 2024	Ostronic Francis Patrick	director	-	A-Award	Buy	8,703	-	-	338,028
Feb 15, 2024	Toig Randall M.	director	-	A-Award	Buy	7,516	-	-	104,891
Feb 15, 2024	STRATTAN CE RICK	director	-	A-Award	Buy	6,963	-	-	286,596
Feb 15, 2024	Wong Vivien	director	-	A-Award	Buy	6,330	-	-	8,818
Feb 15, 2024	CONKLING WILLIAM	director	-	A-Award	Buy	6,330	-	-	16,245
Feb 15, 2024	SHANAHAN WILLIAM S	director	-	A-Award	Buy	8,466	-	-	117,931
Dec 28, 2023	Cross Shawn	director	-	A-Award	Buy	88,910	$2.96	$263.17K	89,910
Dec 28, 2023	Cross Shawn	director	-	A-Award	Buy	72,606	-	-	72,606
Dec 28, 2023	Cross Shawn	director	-		Sell	-	-	-	-
Nov 30, 2023	CONKLING WILLIAM	director	-	A-Award	Buy	7,466	-	-	9,915
Nov 30, 2023	Ostronic Francis Patrick	director	-	A-Award	Buy	10,262	-	-	329,325
Nov 30, 2023	Wong Vivien	director	-	A-Award	Buy	2,488	-	-	2,488
Nov 30, 2023	SHANAHAN WILLIAM S	director	-	A-Award	Buy	9,982	-	-	109,465
Nov 30, 2023	Toig Randall M.	director	-	A-Award	Buy	8,862	-	-	97,375
Nov 30, 2023	Sieger Markus	director	-	A-Award	Buy	16,512	-	-	296,675
Nov 30, 2023	STRATTAN CE RICK	director	-	A-Award	Buy	8,209	-	-	279,633
Oct 31, 2023	STRATTAN CE RICK	director	-	A-Award	Buy	42,599	-	-	271,424
Oct 23, 2023	Rafael Holdings, Inc.	10 percent owner	-	X-InTheMoney	Buy	2,514,970	$0.71	$1.79M	9,029,940
Oct 23, 2023	Rafael Holdings, Inc.	10 percent owner	-	P-Purchase	Buy	2,766,467	$0.95	$2.63M	2,766,467

The last insider sell of Cyclo Therapeutics's stock was made by Cross Shawn on Dec 28 2023, selling - shares at - per share (valued at -). The last insider buy of CYTH was made by Rafael Holdings, Inc. on Oct 23 2023, buying 2,766,467 shares at $0.95 per share (worth $2.63M).

Cyclo Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	7	-	-
Q4 2023	40	12	333.33%
Q3 2023	18	2	900.00%
Q2 2023	28	4	700.00%
Q1 2023	20	-	-
Q4 2022	6	-	-
Q3 2022	4	-	-
Q2 2022	10	-	-
Q1 2022	16	-	-
Q4 2021	12	-	-
Q3 2021	13	-	-
Q2 2021	9	-	-
Q1 2021	16	1	1600.00%
Q4 2020	18	-	-
Q3 2020	16	35	45.71%
Q2 2020	8	-	-
Q3 2019	28	-	-
Q2 2019	14	2	700.00%
Q4 2018	18	1	1800.00%
Q2 2018	20	9	222.22%

7 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Cyclo Therapeutics's insiders, as of Q1 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	-	-	-
Q4 2023	10	-	-
Q3 2023	4	-	-
Q2 2023	16	-	-
Q1 2023	-	-	-
Q4 2022	-	-	-
Q3 2022	1	-	-
Q2 2022	6	-	-
Q1 2022	7	-	-
Q4 2021	12	-	-
Q3 2021	1	-	-
Q2 2021	9	-	-
Q1 2021	10	-	-
Q4 2020	16	-	-
Q3 2020	10	38	26.32%
Q2 2020	6	-	-
Q3 2019	25	-	-
Q2 2019	14	-	-
Q4 2018	18	-	-
Q2 2018	12	-	-

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Cyclo Therapeutics's stocks.

Cyclo Therapeutics Peer Ownership

Ticker	Company
PTPI	Petros Pharmaceuticals, Inc.
IRWD	Ironwood Pharmaceuticals, Inc.
AGRX	Agile Therapeutics, Inc.
ASRT	Assertio Holdings, Inc.
AMRX	Amneal Pharmaceuticals, Inc.
AQST	Aquestive Therapeutics, Inc.
ACRX	Talphera, Inc.
SSIC	Silver Spike Investment Corp.
PAHC	Phibro Animal Health Corporation
ITCI	Intra-Cellular Therapies, Inc.
LFCR	Lifecore Biomedical, Inc.
GHSI	Guardion Health Sciences, Inc.
TKNO	Alpha Teknova, Inc.
EGRX	Eagle Pharmaceuticals, Inc.
LSDI	Lucy Scientific Discovery Inc.

CYTH Ownership FAQ

Who Owns Cyclo Therapeutics?

Cyclo Therapeutics is owned by institutional shareholders (15.33%), insiders (39.91%), and public (44.77%). The largest institutional shareholder of Cyclo Therapeutics is ARMISTICE CAPITAL, LLC (9.47% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.01% of total shares).

Who are the major institutional shareholders of Cyclo Therapeutics?

Cyclo Therapeutics's major institutional shareholders are ARMISTICE CAPITAL, LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, and CITADEL ADVISORS LLC. The top five shareholders own together 15.01% of the company's share outstanding.

How many Cyclo Therapeutics shareholders are there?

As of Mar 2023, there are 16 institutional shareholders of Cyclo Therapeutics.

What percentage of Cyclo Therapeutics is owned by ARMISTICE CAPITAL, LLC?

ARMISTICE CAPITAL, LLC owns 603K shares of Cyclo Therapeutics, representing 9.47% of the company's total shares outstanding, valued at $506.58M (as of Mar 2023).

What percentage of Cyclo Therapeutics is owned by VANGUARD GROUP INC?

As of Mar 2023, VANGUARD GROUP INC holds 253.88K shares of Cyclo Therapeutics (CYTH), compromising 3.99% of the company, valued at $213.29M.

What percentage of Cyclo Therapeutics is owned by GEODE CAPITAL MANAGEMENT, LLC?

GEODE CAPITAL MANAGEMENT, LLC is the third largest holder of Cyclo Therapeutics. The company owns 52.25K of the company's shares outstanding (worth $43.94M).